Description

This issue of Vital Signs, released on May 12, 2008, provides an strategic overview of current market issues facing Merck Schering-Plough's cholesterol drug, Vytorin. Additionally, a company spotlight is provided for Vical, a biopharmaceutical company developing medicines based on the company's proprietary DNA delivery technologies. Reimbursement and regulatory news from the FDA is also provided for the week of April 28 - May 2, 2008.